IBD 50 Stock Natera Zips Into Profit Taking Zone On Its Blowout Quarter Natera's explosive quarterly results are a testament to the growing demand for liquid biopsies in cancer care.
The company's Signatera test has been touted as a game changer, allowing doctors to detect cancer recurrence with unprecedented accuracy.
The sheer scale of Signatera's adoption is undeniable: 34,000 tests were administered in Q2 alone. Natera has undoubtedly found itself at the forefront of a rapidly expanding market.